4wtf › Citations

Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase.

Appleby TC, Perry JK, Murakami E, Barauskas O, Feng J, Cho A, Fox D, Wetmore DR, McGrath ME, Ray AS, Sofia MJ, Swaminathan S, Edwards TE
Science 347 771-5 (2015)
Related entries: 4wt9, 4wta, 4wtc, 4wtd, 4wte, 4wtg, 4wti, 4wtj, 4wtk, 4wtl, 4wtm

Cited: 189 times
EuropePMC logo PMID: 25678663

Abstract

Nucleotide analog inhibitors have shown clinical success in the treatment of hepatitis C virus (HCV) infection, despite an incomplete mechanistic understanding of NS5B, the viral RNA-dependent RNA polymerase. Here we study the details of HCV RNA replication by determining crystal structures of stalled polymerase ternary complexes with enzymes, RNA templates, RNA primers, incoming nucleotides, and catalytic metal ions during both primed initiation and elongation of RNA synthesis. Our analysis revealed that highly conserved active-site residues in NS5B position the primer for in-line attack on the incoming nucleotide. A β loop and a C-terminal membrane-anchoring linker occlude the active-site cavity in the apo state, retract in the primed initiation assembly to enforce replication of the HCV genome from the 3' terminus, and vacate the active-site cavity during elongation. We investigated the incorporation of nucleotide analog inhibitors, including the clinically active metabolite formed by sofosbuvir, to elucidate key molecular interactions in the active site.

Articles - 4wtf mentioned but not cited (2)

  1. Structural Insights into the Binding Modes of Viral RNA-Dependent RNA Polymerases Using a Function-Site Interaction Fingerprint Method for RNA Virus Drug Discovery. Zhao Z, Bourne PE. J Proteome Res 19 4698-4705 (2020)
  2. Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking. Karpiński TM, Ożarowski M, Silva PJ, Stasiewicz M, Alam R, Samad A. Pathogens 12 842 (2023)


Reviews citing this publication (53)

  1. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, Rocchi P, Ng WL. Mol Cell 79 710-727 (2020)
  2. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Te Velthuis AJ, Fodor E. Nat Rev Microbiol 14 479-493 (2016)
  3. RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution. Venkataraman S, Prasad BVLS, Selvarajan R. Viruses 10 E76 (2018)
  4. Structural biology of SARS-CoV-2 and implications for therapeutic development. Yang H, Rao Z. Nat Rev Microbiol 19 685-700 (2021)
  5. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Malone B, Urakova N, Snijder EJ, Campbell EA. Nat Rev Mol Cell Biol 23 21-39 (2022)
  6. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Götte M, Feld JJ. Nat Rev Gastroenterol Hepatol 13 338-351 (2016)
  7. Structural insights into RNA synthesis by the influenza virus transcription-replication machine. Pflug A, Lukarska M, Resa-Infante P, Reich S, Cusack S. Virus Res 234 103-117 (2017)
  8. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Baumert TF, Berg T, Lim JK, Nelson DR. Gastroenterology 156 431-445 (2019)
  9. Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. Saha RP, Sharma AR, Singh MK, Samanta S, Bhakta S, Mandal S, Bhattacharya M, Lee SS, Chakraborty C. Front Pharmacol 11 1258 (2020)
  10. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Jiang Y, Yin W, Xu HE. Biochem Biophys Res Commun 538 47-53 (2021)
  11. A Structural Overview of RNA-Dependent RNA Polymerases from the Flaviviridae Family. Wu J, Liu W, Gong P. Int J Mol Sci 16 12943-12957 (2015)
  12. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A, Svicher V, Costa G, Salpini R, Di Maio VC, Alkhatib M, Ambrosio FA, Santoro MM, Assaraf YG, Alcaro S, Ceccherini-Silberstein F. Drug Resist Updat 53 100721 (2020)
  13. Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA. Viruses 7 5206-5224 (2015)
  14. Dengue Virus Non-Structural Protein 5. El Sahili A, Lescar J. Viruses 9 E91 (2017)
  15. A Structure-Function Diversity Survey of the RNA-Dependent RNA Polymerases From the Positive-Strand RNA Viruses. Jia H, Gong P. Front Microbiol 10 1945 (2019)
  16. Overview of SARS-CoV-2 genome-encoded proteins. Bai C, Zhong Q, Gao GF. Sci China Life Sci 65 280-294 (2022)
  17. Towards a structural understanding of RNA synthesis by negative strand RNA viral polymerases. Reguera J, Gerlach P, Cusack S. Curr Opin Struct Biol 36 75-84 (2016)
  18. Polymerases of paramyxoviruses and pneumoviruses. Fearns R, Plemper RK. Virus Res 234 87-102 (2017)
  19. Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. Picarazzi F, Vicenti I, Saladini F, Zazzi M, Mori M. Molecules 25 E5695 (2020)
  20. RNA Synthesis and Capping by Non-segmented Negative Strand RNA Viral Polymerases: Lessons From a Prototypic Virus. Ogino T, Green TJ. Front Microbiol 10 1490 (2019)
  21. RNA-Dependent RNA Polymerases of Picornaviruses: From the Structure to Regulatory Mechanisms. Ferrer-Orta C, Ferrero D, Verdaguer N. Viruses 7 4438-4460 (2015)
  22. Structure and function of Zika virus NS5 protein: perspectives for drug design. Wang B, Thurmond S, Hai R, Song J. Cell Mol Life Sci 75 1723-1736 (2018)
  23. Structural and Functional Basis of the Fidelity of Nucleotide Selection by Flavivirus RNA-Dependent RNA Polymerases. Selisko B, Papageorgiou N, Ferron F, Canard B. Viruses 10 E59 (2018)
  24. A structural view of the RNA-dependent RNA polymerases from the Flavivirus genus. Lu G, Gong P. Virus Res 234 34-43 (2017)
  25. Using the Hepatitis C Virus RNA-Dependent RNA Polymerase as a Model to Understand Viral Polymerase Structure, Function and Dynamics. Sesmero E, Thorpe IF. Viruses 7 3974-3994 (2015)
  26. Pyrrolo[2,3-d]pyrimidine (7-deazapurine) as a privileged scaffold in design of antitumor and antiviral nucleosides. Perlíková P, Hocek M. Med Res Rev 37 1429-1460 (2017)
  27. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Tamori A, Enomoto M, Kawada N. Mediators Inflamm 2016 6841628 (2016)
  28. Virologic Tools for HCV Drug Resistance Testing. Fourati S, Pawlotsky JM. Viruses 7 6346-6359 (2015)
  29. The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA. Li Y, Yamane D, Masaki T, Lemon SM. Nat Rev Microbiol 13 544-558 (2015)
  30. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Bagaglio S, Uberti-Foppa C, Morsica G. Drugs 77 1043-1055 (2017)
  31. HCV in 2015: Advances in hepatitis C research and treatment. Rehermann B. Nat Rev Gastroenterol Hepatol 13 70-72 (2016)
  32. Structures of the Mononegavirales Polymerases. Liang B. J Virol 94 e00175-20 (2020)
  33. Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. Ploen D, Hildt E. World J Gastroenterol 21 8492-8507 (2015)
  34. Small molecules in the treatment of COVID-19. Lei S, Chen X, Wu J, Duan X, Men K. Signal Transduct Target Ther 7 387 (2022)
  35. COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks. Murugan C, Ramamoorthy S, Kuppuswamy G, Murugan RK, Sivalingam Y, Sundaramurthy A. Int J Biol Macromol 193 1165-1200 (2021)
  36. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. Liu XH, Zhang X, Lu ZH, Zhu YS, Wang T. Biomed Pharmacother 133 111035 (2021)
  37. The uncoupling of catalysis and translocation in the viral RNA-dependent RNA polymerase. Shu B, Gong P. RNA Biol 14 1314-1319 (2017)
  38. Recent advances in understanding hepatitis C. Douam F, Ding Q, Ploss A. F1000Res 5 F1000 Faculty Rev-131 (2016)
  39. Visualizing the Nucleotide Addition Cycle of Viral RNA-Dependent RNA Polymerase. Wu J, Gong P. Viruses 10 (2018)
  40. Dissecting nucleotide selectivity in viral RNA polymerases. Long C, Romero ME, La Rocco D, Yu J. Comput Struct Biotechnol J 19 3339-3348 (2021)
  41. Transcriptional Control and mRNA Capping by the GDP Polyribonucleotidyltransferase Domain of the Rabies Virus Large Protein. Ogino T, Green TJ. Viruses 11 E504 (2019)
  42. Flavivirus RNA-Dependent RNA Polymerase Interacts with Genome UTRs and Viral Proteins to Facilitate Flavivirus RNA Replication. Duan Y, Zeng M, Jiang B, Zhang W, Wang M, Jia R, Zhu D, Liu M, Zhao X, Yang Q, Wu Y, Zhang S, Liu Y, Zhang L, Yu Y, Pan L, Chen S, Cheng A. Viruses 11 E929 (2019)
  43. Hepatitis C Viral Replication Complex. Li HC, Yang CH, Lo SY. Viruses 13 520 (2021)
  44. CoV-er all the bases: Structural perspectives of SARS-CoV-2 RNA synthesis. Malone B, Campbell EA, Darst SA. Enzymes 49 1-37 (2021)
  45. Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review. Srinivasan K, Rao M. Ther Adv Infect Dis 8 20499361211063016 (2021)
  46. Chemical Nature of Metals and Metal-Based Materials in Inactivation of Viruses. Tian H, He B, Yin Y, Liu L, Shi J, Hu L, Jiang G. Nanomaterials (Basel) 12 2345 (2022)
  47. Cystoviral RNA-directed RNA polymerases: Regulation of RNA synthesis on multiple time and length scales. Alphonse S, Ghose R. Virus Res 234 135-152 (2017)
  48. Inhibition of Viral RNA-Dependent RNA Polymerases by Nucleoside Inhibitors: An Illustration of the Unity and Diversity of Mechanisms. Barik S. Int J Mol Sci 23 12649 (2022)
  49. Biochemistry of the Respiratory Syncytial Virus L Protein Embedding RNA Polymerase and Capping Activities. Sutto-Ortiz P, Eléouët JF, Ferron F, Decroly E. Viruses 15 341 (2023)
  50. Is the conquest of Hepatitis C imminent? Rivett L, Alexander G. Expert Rev Mol Med 21 e3 (2019)
  51. Recent Advances in Molecular Mechanisms of Nucleoside Antivirals. Kamzeeva PN, Aralov AV, Alferova VA, Korshun VA. Curr Issues Mol Biol 45 6851-6879 (2023)
  52. Targeting Metalloenzymes: The "Achilles' Heel" of Viruses and Parasites. Moianos D, Prifti GM, Makri M, Zoidis G. Pharmaceuticals (Basel) 16 901 (2023)
  53. Vector-Transmitted Flaviviruses: An Antiviral Molecules Overview. Diani E, Lagni A, Lotti V, Tonon E, Cecchetto R, Gibellini D. Microorganisms 11 2427 (2023)

Articles citing this publication (134)

  1. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, Sun Q, Ming Z, Zhang L, Ge J, Zheng L, Zhang Y, Wang H, Zhu Y, Zhu C, Hu T, Hua T, Zhang B, Yang X, Li J, Yang H, Liu Z, Xu W, Guddat LW, Wang Q, Lou Z, Rao Z. Science 368 779-782 (2020)
  2. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, Wang X, Zhou F, Zhao W, Gao M, Chang S, Xie YC, Tian G, Jiang HW, Tao SC, Shen J, Jiang Y, Jiang H, Xu Y, Zhang S, Zhang Y, Xu HE. Science 368 1499-1504 (2020)
  3. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. J Biol Chem 295 6785-6797 (2020)
  4. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL. J Med Chem 60 1648-1661 (2017)
  5. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP. Cell Rep 32 107940 (2020)
  6. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. Mirza MU, Froeyen M. J Pharm Anal 10 320-328 (2020)
  7. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sacramento CQ, de Melo GR, de Freitas CS, Rocha N, Hoelz LV, Miranda M, Fintelman-Rodrigues N, Marttorelli A, Ferreira AC, Barbosa-Lima G, Abrantes JL, Vieira YR, Bastos MM, de Mello Volotão E, Nunes EP, Tschoeke DA, Leomil L, Loiola EC, Trindade P, Rehen SK, Bozza FA, Bozza PT, Boechat N, Thompson FL, de Filippis AM, Brüning K, Souza TM. Sci Rep 7 40920 (2017)
  8. Structure and function of the Zika virus full-length NS5 protein. Zhao B, Yi G, Du F, Chuang YC, Vaughan RC, Sankaran B, Kao CC, Li P. Nat Commun 8 14762 (2017)
  9. SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Wang W, Zhou Z, Xiao X, Tian Z, Dong X, Wang C, Li L, Ren L, Lei X, Xiang Z, Wang J. Cell Mol Immunol 18 945-953 (2021)
  10. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Stevens LJ, Pruijssers AJ, Lee HW, Gordon CJ, Tchesnokov EP, Gribble J, George AS, Hughes TM, Lu X, Li J, Perry JK, Porter DP, Cihlar T, Sheahan TP, Baric RS, Götte M, Denison MR. Sci Transl Med 14 eabo0718 (2022)
  11. Structure of the human metapneumovirus polymerase phosphoprotein complex. Pan J, Qian X, Lattmann S, El Sahili A, Yeo TH, Jia H, Cressey T, Ludeke B, Noton S, Kalocsay M, Fearns R, Lescar J. Nature 577 275-279 (2020)
  12. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir. Peng Q, Peng R, Yuan B, Wang M, Zhao J, Fu L, Qi J, Shi Y. Innovation (Camb) 2 100080 (2021)
  13. Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate. Deval J, Hong J, Wang G, Taylor J, Smith LK, Fung A, Stevens SK, Liu H, Jin Z, Dyatkina N, Prhavc M, Stoycheva AD, Serebryany V, Liu J, Smith DB, Tam Y, Zhang Q, Moore ML, Fearns R, Chanda SM, Blatt LM, Symons JA, Beigelman L. PLoS Pathog 11 e1004995 (2015)
  14. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. de Freitas CS, Higa LM, Sacramento CQ, Ferreira AC, Reis PA, Delvecchio R, Monteiro FL, Barbosa-Lima G, James Westgarth H, Vieira YR, Mattos M, Rocha N, Hoelz LVB, Leme RPP, Bastos MM, Rodrigues GOL, Lopes CEM, Queiroz-Junior CM, Lima CX, Costa VV, Teixeira MM, Bozza FA, Bozza PT, Boechat N, Tanuri A, Souza TML. PLoS Negl Trop Dis 13 e0007072 (2019)
  15. The role of the priming loop in influenza A virus RNA synthesis. Te Velthuis AJ, Robb NC, Kapanidis AN, Fodor E. Nat Microbiol 1 16029 (2016)
  16. Purification of Zika virus RNA-dependent RNA polymerase and its use to identify small-molecule Zika inhibitors. Xu HT, Hassounah SA, Colby-Germinario SP, Oliveira M, Fogarty C, Quan Y, Han Y, Golubkov O, Ibanescu I, Brenner B, Stranix BR, Wainberg MA. J Antimicrob Chemother 72 727-734 (2017)
  17. Structural snapshots of actively transcribing influenza polymerase. Kouba T, Drncová P, Cusack S. Nat Struct Mol Biol 26 460-470 (2019)
  18. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Shannon A, Fattorini V, Sama B, Selisko B, Feracci M, Falcou C, Gauffre P, El Kazzi P, Delpal A, Decroly E, Alvarez K, Eydoux C, Guillemot JC, Moussa A, Good SS, La Colla P, Lin K, Sommadossi JP, Zhu Y, Yan X, Shi H, Ferron F, Canard B. Nat Commun 13 621 (2022)
  19. Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication. Xu HT, Colby-Germinario SP, Hassounah SA, Fogarty C, Osman N, Palanisamy N, Han Y, Oliveira M, Quan Y, Wainberg MA. Sci Rep 7 6345 (2017)
  20. Single-Cell Virology: On-Chip Investigation of Viral Infection Dynamics. Guo F, Li S, Caglar MU, Mao Z, Liu W, Woodman A, Arnold JJ, Wilke CO, Huang TJ, Cameron CE. Cell Rep 21 1692-1704 (2017)
  21. Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus. Tchesnokov EP, Raeisimakiani P, Ngure M, Marchant D, Götte M. Sci Rep 8 3970 (2018)
  22. Structure of a Thermostable Group II Intron Reverse Transcriptase with Template-Primer and Its Functional and Evolutionary Implications. Stamos JL, Lentzsch AM, Lambowitz AM. Mol Cell 68 926-939.e4 (2017)
  23. The C-terminal 18 Amino Acid Region of Dengue Virus NS5 Regulates its Subcellular Localization and Contains a Conserved Arginine Residue Essential for Infectious Virus Production. Tay MY, Smith K, Ng IH, Chan KW, Zhao Y, Ooi EE, Lescar J, Luo D, Jans DA, Forwood JK, Vasudevan SG. PLoS Pathog 12 e1005886 (2016)
  24. Blocking Zika virus vertical transmission. Mesci P, Macia A, Moore SM, Shiryaev SA, Pinto A, Huang CT, Tejwani L, Fernandes IR, Suarez NA, Kolar MJ, Montefusco S, Rosenberg SC, Herai RH, Cugola FR, Russo FB, Sheets N, Saghatelian A, Shresta S, Momper JD, Siqueira-Neto JL, Corbett KD, Beltrão-Braga PCB, Terskikh AV, Muotri AR. Sci Rep 8 1218 (2018)
  25. A Conserved Pocket in the Dengue Virus Polymerase Identified through Fragment-based Screening. Noble CG, Lim SP, Arora R, Yokokawa F, Nilar S, Seh CC, Wright SK, Benson TE, Smith PW, Shi PY. J Biol Chem 291 8541-8548 (2016)
  26. Backtracking behavior in viral RNA-dependent RNA polymerase provides the basis for a second initiation site. Dulin D, Vilfan ID, Berghuis BA, Poranen MM, Depken M, Dekker NH. Nucleic Acids Res 43 10421-10429 (2015)
  27. Predicting Zika virus structural biology: Challenges and opportunities for intervention. Cox BD, Stanton RA, Schinazi RF. Antivir Chem Chemother 24 118-126 (2015)
  28. A dual-functional priming-capping loop of rhabdoviral RNA polymerases directs terminal de novo initiation and capping intermediate formation. Ogino M, Gupta N, Green TJ, Ogino T. Nucleic Acids Res 47 299-309 (2019)
  29. A Mechanism for Priming and Realignment during Influenza A Virus Replication. Oymans J, Te Velthuis AJW. J Virol 92 e01773-17 (2018)
  30. Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor. Kuhlmann FM, Robinson JI, Bluemling GR, Ronet C, Fasel N, Beverley SM. Proc Natl Acad Sci U S A 114 E811-E819 (2017)
  31. Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2'-modified nucleotide analogues. Potisopon S, Ferron F, Fattorini V, Selisko B, Canard B. Antiviral Res 140 25-36 (2017)
  32. The Structure of the RNA-Dependent RNA Polymerase of a Permutotetravirus Suggests a Link between Primer-Dependent and Primer-Independent Polymerases. Ferrero DS, Buxaderas M, Rodríguez JF, Verdaguer N. PLoS Pathog 11 e1005265 (2015)
  33. Discovery of a small molecule inhibitor targeting dengue virus NS5 RNA-dependent RNA polymerase. Shimizu H, Saito A, Mikuni J, Nakayama EE, Koyama H, Honma T, Shirouzu M, Sekine SI, Shioda T. PLoS Negl Trop Dis 13 e0007894 (2019)
  34. RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2. Mishra A, Rathore AS. J Biomol Struct Dyn 40 6039-6051 (2022)
  35. Cooperative motion of a key positively charged residue and metal ions for DNA replication catalyzed by human DNA Polymerase-η. Genna V, Gaspari R, Dal Peraro M, De Vivo M. Nucleic Acids Res 44 2827-2836 (2016)
  36. Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2. Koulgi S, Jani V, Uppuladinne V N M, Sonavane U, Joshi R. PLoS One 16 e0251801 (2021)
  37. In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase. Doharey PK, Singh V, Gedda MR, Sahoo AK, Varadwaj PK, Sharma B. J Biomol Struct Dyn 40 5588-5605 (2022)
  38. Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an in silico perspective. Ogunyemi OM, Gyebi GA, Elfiky AA, Afolabi SO, Ogunro OB, Adegunloye AP, Ibrahim IM. Antivir Chem Chemother 28 2040206620984076 (2020)
  39. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. Gordon CJ, Lee HW, Tchesnokov EP, Perry JK, Feng JY, Bilello JP, Porter DP, Götte M. J Biol Chem 298 101529 (2022)
  40. Hydrogen/Deuterium Exchange Kinetics Demonstrate Long Range Allosteric Effects of Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase. Deredge D, Li J, Johnson KA, Wintrode PL. J Biol Chem 291 10078-10088 (2016)
  41. Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2. Arba M, Wahyudi ST, Brunt DJ, Paradis N, Wu C. Comput Biol Med 129 104156 (2021)
  42. A nucleobase-binding pocket in a viral RNA-dependent RNA polymerase contributes to elongation complex stability. Shi W, Ye HQ, Deng CL, Li R, Zhang B, Gong P. Nucleic Acids Res 48 1392-1405 (2020)
  43. Crystal Structure of Classical Swine Fever Virus NS5B Reveals a Novel N-Terminal Domain. Li W, Wu B, Soca WA, An L. J Virol 92 e00324-18 (2018)
  44. SARS-CoV-2 infects human brain organoids causing cell death and loss of synapses that can be rescued by treatment with Sofosbuvir. Mesci P, de Souza JS, Martin-Sancho L, Macia A, Saleh A, Yin X, Snethlage C, Adams JW, Avansini SH, Herai RH, Almenar-Queralt A, Pu Y, Szeto RA, Goldberg G, Bruck PT, Papes F, Chanda SK, Muotri AR. PLoS Biol 20 e3001845 (2022)
  45. The structural model of Zika virus RNA-dependent RNA polymerase in complex with RNA for rational design of novel nucleotide inhibitors. Šebera J, Dubankova A, Sychrovský V, Ruzek D, Boura E, Nencka R. Sci Rep 8 11132 (2018)
  46. Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase Allosterically Block the Transition from Initiation to Elongation. Li J, Johnson KA. J Biol Chem 291 10067-10077 (2016)
  47. A unique intra-molecular fidelity-modulating mechanism identified in a viral RNA-dependent RNA polymerase. Liu W, Shi X, Gong P. Nucleic Acids Res 46 10840-10854 (2018)
  48. Hepatitis C virus replicative double-stranded RNA is a potent interferon inducer that triggers interferon production through MDA5. Du X, Pan T, Xu J, Zhang Y, Song W, Yi Z, Yuan Z. J Gen Virol 97 2868-2882 (2016)
  49. Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2. Dwivedy A, Mariadasse R, Ahmad M, Chakraborty S, Kar D, Tiwari S, Bhattacharyya S, Sonar S, Mani S, Tailor P, Majumdar T, Jeyakanthan J, Biswal BK. PLoS Comput Biol 17 e1009384 (2021)
  50. Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase. Xu HT, Colby-Germinario SP, Hassounah S, Quashie PK, Han Y, Oliveira M, Stranix BR, Wainberg MA. Antimicrob Agents Chemother 60 600-608 (2016)
  51. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, Aranday-Cortes E, Da Silva Filipe A, McLauchlan J, Smith D, Irving W, Cunningham M, Ansari A, Barnes E, Foster GR. Gastroenterology 157 692-704.e9 (2019)
  52. Identification and characterization of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach. Barage S, Karthic A, Bavi R, Desai N, Kumar R, Kumar V, Lee KW. J Biomol Struct Dyn 40 2557-2574 (2022)
  53. Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complex. Wu J, Wang H, Liu Q, Li R, Gao Y, Fang X, Zhong Y, Wang M, Wang Q, Rao Z, Gong P. Cell Rep 37 109882 (2021)
  54. Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs. Chen Z, Cox BD, Garnier-Amblard EC, McBrayer TR, Coats SJ, Schinazi RF, Amblard F. Bioorg Med Chem Lett 27 5296-5299 (2017)
  55. The hepatitis C virus RNA-dependent RNA polymerase directs incoming nucleotides to its active site through magnesium-dependent dynamics within its F motif. Ben Ouirane K, Boulard Y, Bressanelli S. J Biol Chem 294 7573-7587 (2019)
  56. NS3 from Hepatitis C Virus Strain JFH-1 Is an Unusually Robust Helicase That Is Primed To Bind and Unwind Viral RNA. Zhou T, Ren X, Adams RL, Pyle AM. J Virol 92 e01253-17 (2018)
  57. C-Terminal Auto-Regulatory Motif of Hepatitis C Virus NS5B Interacts with Human VAPB-MSP to Form a Dynamic Replication Complex. Gupta G, Song J. PLoS One 11 e0147278 (2016)
  58. Nucleoside Analogs with Selective Antiviral Activity against Dengue Fever and Japanese Encephalitis Viruses. Zandi K, Bassit L, Amblard F, Cox BD, Hassandarvish P, Moghaddam E, Yueh A, Libanio Rodrigues GO, Passos I, Costa VV, AbuBakar S, Zhou L, Kohler J, Teixeira MM, Schinazi RF. Antimicrob Agents Chemother 63 e00397-19 (2019)
  59. Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues. Perišić O. Biomolecules 10 E1346 (2020)
  60. Molecular Dynamics Simulations Reveal the Interaction Fingerprint of Remdesivir Triphosphate Pivotal in Allosteric Regulation of SARS-CoV-2 RdRp. Srivastava M, Mittal L, Kumari A, Asthana S. Front Mol Biosci 8 639614 (2021)
  61. Structural basis for template switching by a group II intron-encoded non-LTR-retroelement reverse transcriptase. Lentzsch AM, Stamos JL, Yao J, Russell R, Lambowitz AM. J Biol Chem 297 100971 (2021)
  62. Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains. Trémeaux P, Caporossi A, Ramière C, Santoni E, Tarbouriech N, Thélu MA, Fusillier K, Geneletti L, François O, Leroy V, Burmeister WP, André P, Morand P, Larrat S. Clin Microbiol Infect 22 460.e1-460.e10 (2016)
  63. Congress Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Sagan SM, Dupont B, Grebely J, Krajden M, MacParland SA, Raven JF, Saeed S, Feld JJ, Tyrrell DL, Wilson JA. Can J Gastroenterol Hepatol 2016 5743521 (2016)
  64. Potential Novel Thioether-Amide or Guanidine-Linker Class of SARS-CoV-2 Virus RNA-Dependent RNA Polymerase Inhibitors Identified by High-Throughput Virtual Screening Coupled to Free-Energy Calculations. Jukič M, Janežič D, Bren U. Int J Mol Sci 22 11143 (2021)
  65. Resistance to excision determines efficiency of hepatitis C virus RNA-dependent RNA polymerase inhibition by nucleotide analogs. Villalba B, Li J, Johnson KA. J Biol Chem 295 10112-10124 (2020)
  66. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. Uchida Y, Nakamura S, Kouyama JI, Naiki K, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Hedskog C, Brainard D, Mo H, Mochida S. Sci Rep 8 8818 (2018)
  67. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2. Feng JY, Du Pont V, Babusis D, Gordon CJ, Tchesnokov EP, Perry JK, Duong V, Vijjapurapu A, Zhao X, Chan J, Cohen C, Juneja K, Cihlar T, Götte M, Bilello JP. Molecules 27 4212 (2022)
  68. A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5B and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin. Kulkarni AS, Damha MJ, Schinazi RF, Mo H, Doehle B, Sagan SM, Götte M. Antimicrob Agents Chemother 60 2018-2027 (2016)
  69. AZT acts as an anti-influenza nucleotide triphosphate targeting the catalytic site of A/PR/8/34/H1N1 RNA dependent RNA polymerase. Pagadala NS. J Comput Aided Mol Des 33 387-404 (2019)
  70. Activity of Selected Nucleoside Analogue ProTides against Zika Virus in Human Neural Stem Cells. Bernatchez JA, Coste M, Beck S, Wells GA, Luna LA, Clark AE, Zhu Z, Hecht D, Rich JN, Sohl CD, Purse BW, Siqueira-Neto JL. Viruses 11 E365 (2019)
  71. Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2. Jena NR, Pant S, Srivastava HK. J Biomol Struct Dyn 40 6381-6397 (2022)
  72. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Abdurakhmanov E, Øie Solbak S, Danielson UH. Viruses 9 E151 (2017)
  73. Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. Maheden K, Todd B, Gordon CJ, Tchesnokov EP, Götte M. Enzymes 49 315-354 (2021)
  74. Mechanism of reaction of RNA-dependent RNA polymerase from SARS-CoV-2. Aranda J, Wieczór M, Terrazas M, Brun-Heath I, Orozco M. Chem Catal 2 1084-1099 (2022)
  75. Phosphorylation at the N-terminal finger subdomain of a viral RNA-dependent RNA polymerase. Hernández S, Figueroa D, Correa S, Díaz A, Aguayo D, Villanueva RA. Biochem Biophys Res Commun 466 21-27 (2015)
  76. Sugar modified pyrimido[4,5-b]indole nucleosides: synthesis and antiviral activity. Konč J, Tichý M, Pohl R, Hodek J, Džubák P, Hajdúch M, Hocek M. Medchemcomm 8 1856-1862 (2017)
  77. 2'-C-methylated nucleotides terminate virus RNA synthesis by preventing active site closure of the viral RNA-dependent RNA polymerase. Boehr AK, Arnold JJ, Oh HS, Cameron CE, Boehr DD. J Biol Chem 294 16897-16907 (2019)
  78. Identification of a Small Interface between the Methyltransferase and RNA Polymerase of NS5 that is Essential for Zika Virus Replication. Rusanov T, Kent T, Saeed M, Hoang TM, Thomas C, Rice CM, Pomerantz RT. Sci Rep 8 17384 (2018)
  79. Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic Fever Virus full-length L-protein. Tchesnokov EP, Bailey-Elkin BA, Mark BL, Götte M. PLoS Negl Trop Dis 14 e0008283 (2020)
  80. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B. Bessa LM, Launay H, Dujardin M, Cantrelle FX, Lippens G, Landrieu I, Schneider R, Hanoulle X. J Biol Chem 292 18024-18043 (2017)
  81. Structure of acid deoxyribonuclease. Varela-Ramirez A, Abendroth J, Mejia AA, Phan IQ, Lorimer DD, Edwards TE, Aguilera RJ. Nucleic Acids Res 45 6217-6227 (2017)
  82. The role of the priming loop in Influenza A virus RNA synthesis. Te Velthuis AJ, Robb NC, Kapanidis AN, Fodor E. Nat Microbiol 1 16029 (2016)
  83. An all-atom, active site exploration of antiviral drugs that target Flaviviridae polymerases. Valdés JJ, Gil VA, Butterill PT, Růžek D. J Gen Virol 97 2552-2565 (2016)
  84. Characterization of SARS-CoV-2 replication complex elongation and proofreading activity. Jones AN, Mourão A, Czarna A, Matsuda A, Fino R, Pyrc K, Sattler M, Popowicz GM. Sci Rep 12 9593 (2022)
  85. Comparison of RNA synthesis initiation properties of non-segmented negative strand RNA virus polymerases. Shareef AM, Ludeke B, Jordan P, Deval J, Fearns R. PLoS Pathog 17 e1010151 (2021)
  86. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp). Karthic A, Kesarwani V, Singh RK, Yadav PK, Chaturvedi N, Chauhan P, Yadav BS, Kushwaha SK. Molecules 27 801 (2022)
  87. Crystal structure of a tick-borne flavivirus RNA-dependent RNA polymerase suggests a host adaptation hotspot in RNA viruses. Yang J, Jing X, Yi W, Li XD, Yao C, Zhang B, Zheng Z, Wang H, Gong P. Nucleic Acids Res 49 1567-1580 (2021)
  88. Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents. Mahboubi Rabbani SMI, Vahabpour R, Hajimahdi Z, Zarghi A. Iran J Pharm Res 18 1790-1802 (2019)
  89. Diastereo- and enantioselective synthesis of compounds with a trifluoromethyl- and fluoro-substituted carbon centre. Xu S, Del Pozo J, Romiti F, Fu Y, Mai BK, Morrison RJ, Lee K, Hu S, Koh MJ, Lee J, Li X, Liu P, Hoveyda AH. Nat Chem 14 1459-1469 (2022)
  90. Evidence for Internal Initiation of RNA Synthesis by the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B In Cellulo. Schult P, Nattermann M, Lauber C, Seitz S, Lohmann V. J Virol 93 e00525-19 (2019)
  91. Molecular architecture of the Chikungunya virus replication complex. Tan YB, Chmielewski D, Law MCY, Zhang K, He Y, Chen M, Jin J, Luo D. Sci Adv 8 eadd2536 (2022)
  92. Setomimycin as a potential molecule for COVID‑19 target: in silico approach and in vitro validation. Manhas RS, Tiwari H, Noor M, Ahmed A, Vishwakarma J, Tripathi RBM, Ramachandran R, Madishetti S, Mukherjee D, Nargotra A, Chaubey A. Mol Divers 27 619-633 (2023)
  93. Snapshots of a Non-Canonical RdRP in Action. Ferrero DS, Falqui M, Verdaguer N. Viruses 13 1260 (2021)
  94. Sofosbuvir Selects for Drug-Resistant Amino Acid Variants in the Zika Virus RNA-Dependent RNA-Polymerase Complex In Vitro. Boccuto A, Dragoni F, Picarazzi F, Lai A, Della Ventura C, Veo C, Giammarino F, Saladini F, Zehender G, Zazzi M, Mori M, Vicenti I. Int J Mol Sci 22 2670 (2021)
  95. Structural basis for substrate selection by the SARS-CoV-2 replicase. Malone BF, Perry JK, Olinares PDB, Lee HW, Chen J, Appleby TC, Feng JY, Bilello JP, Ng H, Sotiris J, Ebrahim M, Chua EYD, Mendez JH, Eng ET, Landick R, Götte M, Chait BT, Campbell EA, Darst SA. Nature 614 781-787 (2023)
  96. Structure of plant RNA-DEPENDENT RNA POLYMERASE 2, an enzyme involved in small interfering RNA production. Du X, Yang Z, Ariza AJF, Wang Q, Xie G, Li S, Du J. Plant Cell 34 2140-2149 (2022)
  97. The unexpected structures of hepatitis C virus envelope proteins. Wang Y, Wang J, Wu S, Zhu H. Exp Ther Med 14 1859-1865 (2017)
  98. A conserved arginine in NS5 binds genomic 3' stem-loop RNA for primer-independent initiation of flavivirus RNA replication. Wang S, Chan KWK, Tan MJA, Flory C, Luo D, Lescar J, Forwood JK, Vasudevan SG. RNA 28 177-193 (2022)
  99. An induced-fit de novo initiation mechanism suggested by a pestivirus RNA-dependent RNA polymerase. Zhang BY, Liu W, Jia H, Lu G, Gong P. Nucleic Acids Res 49 8811-8821 (2021)
  100. Biochemical Basis of Vosevi, a New Treatment for Hepatitis CPublished as part of the Biochemistry series "Biochemistry to Bedside". Besandre R, Liu HW. Biochemistry 57 479-480 (2018)
  101. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase. Prussia AJ, Chennamadhavuni S. J Chem Inf Model 61 1402-1411 (2021)
  102. Distinctive features of the respiratory syncytial virus priming loop compared to other non-segmented negative strand RNA viruses. Cressey TN, Shareef AM, Kleiner VA, Noton SL, Byrne PO, McLellan JS, Mühlberger E, Fearns R. PLoS Pathog 18 e1010451 (2022)
  103. Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients. Gömer A, Klöhn M, Jagst M, Nocke MK, Nocke MK, Pischke S, Horvatits T, Schulze Zur Wiesch J, Müller T, Hardtke S, Cornberg M, Wedemeyer H, Behrendt P, Steinmann E, Todt D. Hepatology 78 1882-1895 (2023)
  104. Molecular basis for the initiation of DNA primer synthesis. Li AWH, Zabrady K, Bainbridge LJ, Zabrady M, Naseem-Khan S, Berger MB, Kolesar P, Cisneros GA, Doherty AJ. Nature 605 767-773 (2022)
  105. Positive strand RNA viruses differ in the constraints they place on the folding of their negative strand. Herod MR, Ward JC, Tuplin A, Harris M, Stonehouse NJ, McCormick CJ. RNA 28 1359-1376 (2022)
  106. The low-resolution structural models of hepatitis C virus RNA subdomain 5BSL3.2 and its distal complex with domain 3'X point to conserved regulatory mechanisms within the Flaviviridae family. Castillo-Martínez J, Fan L, Szewczyk MP, Wang YX, Gallego J. Nucleic Acids Res 50 2287-2301 (2022)
  107. Within and Beyond the Nucleotide Addition Cycle of Viral RNA-dependent RNA Polymerases. Gong P. Front Mol Biosci 8 822218 (2021)
  108. Crystal structure of a pre-chemistry viral RNA-dependent RNA polymerase suggests participation of two basic residues in catalysis. Li R, Wang M, Gong P. Nucleic Acids Res 50 12389-12399 (2022)
  109. Discovery of 2'-α-C-Methyl-2'-β-C-fluorouridine Phosphoramidate Prodrugs as Inhibitors of Hepatitis C Virus. Zeng D, Zhang R, Nie Q, Cao L, Shang L, Yin Z. ACS Med Chem Lett 7 1197-1201 (2016)
  110. Discovery of Novel 3-Hydroxyquinazoline-2,4(1H,3H)-Dione Derivatives: A Series of Metal Ion Chelators with Potent Anti-HCV Activities. Cao Y, Aimaiti A, Zhu Z, Zhou L, Ye D. Int J Mol Sci 23 5930 (2022)
  111. Discovery of a 2'-fluoro-2'-C-methyl C-nucleotide HCV polymerase inhibitor and a phosphoramidate prodrug with favorable properties. Kirschberg TA, Metobo S, Clarke MO, Aktoudianakis V, Babusis D, Barauskas O, Birkus G, Butler T, Byun D, Chin G, Doerffler E, Edwards TE, Fenaux M, Lee R, Lew W, Mish MR, Murakami E, Park Y, Squires NH, Tirunagari N, Wang T, Whitcomb M, Xu J, Yang H, Ye H, Zhang L, Appleby TC, Feng JY, Ray AS, Cho A, Kim CU. Bioorg Med Chem Lett 27 1840-1847 (2017)
  112. Discovery of anti-influenza nucleoside triphosphates targeting the catalytic site of A/PR/8/34/H1N1 polymerase. Pagadala NS, Bhat R, Kumar D J, Landi A. Med Chem Res 29 1463-1477 (2020)
  113. Exploring Evolutionary Constraints in the Proteomes of Zika, Dengue, and Other Flaviviruses to Find Fitness-Critical Sites. Nunez-Castilla J, Rahaman J, Ahrens JB, Balbin CA, Siltberg-Liberles J. J Mol Evol 88 399-414 (2020)
  114. Molecular Characterization of Hepatitis C Virus for Developed Antiviral Agents Resistance Mutations and New Insights into in-silico Prediction Studies. El-Sokkary MMA, Gotina L, Al-Sanea MM, Pae AN, Elbargisy RM. Infect Drug Resist 13 4235-4248 (2020)
  115. Proline to Threonine Mutation at Position 162 of NS5B of Classical Swine Fever Virus Vaccine C Strain Promoted Genome Replication and Infectious Virus Production by Facilitating Initiation of RNA Synthesis. Pang H, Li L, Liu H, Pan Z. Viruses 13 1523 (2021)
  116. Ribosome Pausing at Inefficient Codons at the End of the Replicase Coding Region Is Important for Hepatitis C Virus Genome Replication. Gerresheim GK, Hess CS, Shalamova LA, Fricke M, Marz M, Andreev DE, Shatsky IN, Niepmann M. Int J Mol Sci 21 E6955 (2020)
  117. Seeking antiviral drugs to inhibit SARS-CoV-2 RNA dependent RNA polymerase: A molecular docking analysis. Khater I, Nassar A. PLoS One 17 e0268909 (2022)
  118. Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels. Yao X, Gao S, Wang J, Li Z, Huang J, Wang Y, Wang Z, Chen J, Fan X, Wang W, Jin X, Pan X, Yu Y, Lagrutta A, Yan N. Cell 185 4801-4810.e13 (2022)
  119. Structural biology. Kickstarting a viral RNA polymerase. Bressanelli S. Science 347 715-716 (2015)
  120. Letter A practical approach to generate suitable de novo synthesis RNA template for a flavivirus RNA-dependent RNA polymerase. Shi W, Gong P. Virol Sin 32 331-334 (2017)
  121. Akt Phosphorylation of Hepatitis C Virus NS5B Regulates Polymerase Activity and Hepatitis C Virus Infection. Sabariegos R, Albentosa-González L, Palmero B, Clemente-Casares P, Ramírez E, García-Crespo C, Gallego I, de Ávila AI, Perales C, Domingo E, Mas A. Front Microbiol 12 754664 (2021)
  122. From Oxetane to Thietane: Extending the Antiviral Spectrum of 2'-Spirocyclic Uridines by Substituting Oxygen with Sulfur. Grosse S, Tahri A, Raboisson P, Houpis Y, Stoops B, Jacoby E, Neefs JM, Van Loock M, Goethals O, Geluykens P, Bonfanti JF, Jonckers THM. ACS Med Chem Lett 13 1879-1884 (2022)
  123. GDP polyribonucleotidyltransferase domain of vesicular stomatitis virus polymerase regulates leader-promoter escape and polyadenylation-coupled termination during stop-start transcription. Ogino M, Green TJ, Ogino T. PLoS Pathog 18 e1010287 (2022)
  124. Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotide. Sherwood AV, Rivera-Rangel LR, Ryberg LA, Larsen HS, Anker KM, Costa R, Vågbø CB, Jakljevič E, Pham LV, Fernandez-Antunez C, Indrisiunaite G, Podolska-Charlery A, Grothen JER, Langvad NW, Fossat N, Offersgaard A, Al-Chaer A, Nielsen L, Kuśnierczyk A, Sølund C, Weis N, Gottwein JM, Holmbeck K, Bottaro S, Ramirez S, Bukh J, Scheel TKH, Vinther J. Nature 619 811-818 (2023)
  125. Hydrogen Bonding (Base Pairing) in Antiviral Activity. De Clercq E. Viruses 15 1145 (2023)
  126. In silico design of a novel nucleotide antiviral agent by free energy perturbation. Patel D, Cox BD, Kasthuri M, Mengshetti S, Bassit L, Verma K, Ollinger-Russell O, Amblard F, Schinazi RF. Chem Biol Drug Des 99 801-815 (2022)
  127. RNA-Dependent RNA Polymerase from Heterobasidion RNA Virus 6 Is an Active Replicase In Vitro. Levanova AA, Vainio EJ, Hantula J, Poranen MM. Viruses 13 1738 (2021)
  128. RNA-Dependent RNA Polymerase of the Second Human Pegivirus Exhibits a High-Fidelity Feature. Chen S, Wu J, Yang X, Sun Q, Liu S, Rashid F, Dzakah EE, Wang H, Wang J, Gong P, Tang S. Microbiol Spectr 10 e0272922 (2022)
  129. Recapitulating Trafficking of Nucleosides Into the Active Site of Polymerases of RNA Viruses: The Challenge and the Prize. Boulard Y, Bressanelli S. Front Med Technol 3 705875 (2021)
  130. SARS-CoV2 billion-compound docking. Rogers DM, Agarwal R, Vermaas JV, Smith MD, Rajeshwar RT, Cooper C, Sedova A, Boehm S, Baker M, Glaser J, Smith JC. Sci Data 10 173 (2023)
  131. Structural basis of transition from initiation to elongation in de novo viral RNA-dependent RNA polymerases. Wu J, Wang X, Liu Q, Lu G, Gong P. Proc Natl Acad Sci U S A 120 e2211425120 (2023)
  132. The Inhibitory Potential of 2'-dihalo Ribonucleotides against HCV: Molecular Docking, Molecular Simulations, MM-BPSA, and DFT Studies. Khalil A, El-Khouly AS, Elkaeed EB, Eissa IH. Molecules 27 4530 (2022)
  133. Unusual substructure conformations observed in crystal structures of a dicistrovirus RNA-dependent RNA polymerase suggest contribution of the N-terminal extension in proper folding. Fang X, Lu G, Deng Y, Yang S, Hou C, Gong P. Virol Sin 38 531-540 (2023)
  134. Viral Capsid and Polymerase in Reoviridae. Liu H, Cheng L. Subcell Biochem 99 525-552 (2022)


Quick links